USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance
USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance
Overview
Nutritional supplements maker's fiscal Q2 sales fell 5% yr/yr amid weaker Hiya and Rise performance
Company posted a net loss, including preliminary non-cash impairment charge related to Hiya
Fiscal 2026 outlook lowered for sales and earnings due to Hiya and Rise underperformance
Outlook
USANA cuts 2026 consolidated net sales outlook to $910 mln from $925 mln-$1.0 bln
Company lowers 2026 net (loss) earnings forecast to $(11) mln from $20 mln-$27 mln
USANA expects 2026 adjusted diluted EPS of $0.76, down from $1.95-$2.29 prior view
Result Drivers
HIYA WEAKNESS - Hiya's performance was pressured by a challenging digital marketing environment, impacting topline, subscriber growth, and margins
RISE WELLNESS DISRUPTION - Rise Wellness saw a packaging-related disruption that affected commercial execution during the quarter
IMPAIRMENT CHARGE - Co recorded a preliminary non-cash impairment charge for Hiya, reflecting recent performance and changes in near-term forecasts
Company press release: ID:nBw3tVm09a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Miss | $223 mln | $235.003 mln (1 Analyst) |
Q2 Loss Per Share |
| $1.16 |
|
Q2 Net Earnings |
| -$21.40 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for USANA Health Sciences Inc is $39.00, about 70.8% above its August 3 closing price of $22.84
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
Aug 3 - Medifast Q2 revenue falls 28% as active coaches drop
Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies
Aug 3 - QHSLab's Q2 revenue rises on ISP growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on USANA Health Sciences
See all newsBrief: Usana Schedules Third Quarter 2026 Earnings Release And Conference Call
Brief: Usana Health Sciences - Enters First Amendment To Credit Agreement On Sept 30, 2026 - SEC Filing
USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance
Brief: USANA Health Sciences Q2 EPS USD -1.16
Usana Health Sciences Inc Expected To Post Earnings Of 43 Cents A Share: Earnings Preview